| CEO: | Jeremy Skillington |
| CFO: | Ian O’Connel |
| Executive Chairman: | Cathal Friel |
| Independent Non-Executive Director: | Edward Gibson |
| Independent Non-Executive Director: | Luke O’Neill |
| Independent Non-Executive Director: | Brendan Buckley |
| Non-Executive Dir: |
| Address: | 40 Bank Street, Floor 24, London, United Kingdom, E14 5NR |
| Phone: | +44 (0)20 7183 1499 |
| Website: | http://www.poolbegpharma.com/ |
| Sector: | Pharma and Biotech(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BKPG7Z60 |
| Currency | UK Pounds |
| Share Price | 4.35p |
| Change Today | -0.20p |
| % Change | -4.40 % |
| 52 Week High | 4.50 |
| 52 Week Low | 4.20 |
| Volume | 850,373 |
| Shares Issued | 705.10m |
| Market Cap | £30.67m |
| Beta | 0.00 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 15:50 | 3,597 @ 4.29p |
| 15:32 | 89,073 @ 4.48p |
| 14:36 | 6,000 @ 4.48p |
| 14:36 | 554 @ 4.29p |
| 14:26 | 822 @ 4.50p |
| CEO | Jeremy Skillington |
| CFO | Ian O’Connel |
You are here: research